Modification of multidrug resistance of tumor cells by ionizing radiation

Cancer Chemother Pharmacol. 2008 Jan;61(1):15-21. doi: 10.1007/s00280-007-0439-2. Epub 2007 Mar 14.

Abstract

Purpose: The effect of ionizing radiation on multidrug resistance (MDR) of human larynx cancer HEp-2 cells has been investigated. We studied the dependence of the radiation effect on radiation dose, time after irradiation and cell density.

Methods: MDR was determined from an increase in cell sensitivity to daunorubicin, taxol and vincristine by the inhibitors of multidrug resistance cyclosporin A and avermectin B(1), and from the suppression by cyclosporin A of the transport of rhodamine 123 out of the cells. The cells were irradiated with X-ray beams (dose rate 1.12 Gy min(-1)) at room temperature.

Results: It was shown that, at 8 and 16 h after irradiation with doses up to 4 Gy, the multidrug resistance of cells increases, and at 24 h it decreases to the control level. The effect was maximal by 16 h after irradiation with a dose of 1 Gy. Both, the contribution of active transport to the rate of rhodamine 123 efflux from cells and their resistance to vincristine, increased. The effect of irradiation on multidrug resistance of HEp-2 cells depended on the density of cells on the substrate, being maximal at a density of 80,000-100,000 cm(-2).

Conclusion: The irradiation-induced changes in the MDR of tumor cells should be taken into account when combining radiotherapy with chemotherapy. It was assumed that the dependence of multidrug resistance of HEp-2 cells on radiation dose and cell density is determined by changes in the amount of reactive oxygen species in the cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / therapeutic use*
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Cell Count
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Cyclosporine
  • Daunorubicin / therapeutic use
  • Dose-Response Relationship, Radiation
  • Drug Resistance, Multiple / radiation effects*
  • Drug Resistance, Neoplasm / radiation effects*
  • Humans
  • Laryngeal Neoplasms / therapy*
  • Paclitaxel / therapeutic use
  • Radiation, Ionizing
  • Reactive Oxygen Species / radiation effects
  • Rhodamine 123 / metabolism
  • Time Factors
  • Vincristine / therapeutic use

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Phytogenic
  • Reactive Oxygen Species
  • Rhodamine 123
  • Vincristine
  • Cyclosporine
  • Paclitaxel
  • Daunorubicin